<DOC>
	<DOCNO>NCT00343044</DOCNO>
	<brief_summary>The purpose study evaluate clinical safety toxicity intravenous bevacizumab ( Days 1 15 28 day cycle ) combination weekly topotecan ( Days 1 , 8 , 15 28 day cycle ) patient platinum resistant recurrent ovarian , fallopian tube primary peritoneal cancer .</brief_summary>
	<brief_title>Ph II Study Wkly Topotecan + Bevacizumab Plat . Resistant/Recurrent Gyn Cancers</brief_title>
	<detailed_description>This study design Phase 2 study . There publish data toxicity combination bevacizumab topotecan therapy . Based data combine bevacizumab chemotherapy agent non-gynecologic solid tumor , likely toxicity combination two drug great individual toxicity drug . The toxicity agents quite different . Specifically toxicity combination study use dose bevacizumab use previous phase II study ovarian cancer , e.g . equivalent 5 mg/kg weekly treatment give least every 3 week . In study , since topotecan give week 1,2 3 every 4 week cycle , convenient give bevacizumab 10 mg/kg IV every week .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>must receive primary taxane platinumbased chemotherapy 1 chemotherapy regimen must platinum resistant disease ( define recurrence within 6 month receive platinum base chemotherapy , first second line ) must measurable disease ( great 20mm conventional technique 10mm spiral CT ) OR elevate CA125 ( &gt; 100 two occasion least one week apart performance status great equal 70 % prior treatment antiangiogenesis agent treatment &gt; 2 cytotoxic regimen ( include primary platinum taxane chemotherapy ) evidence malignancy within 3 year study enrollment history abdominal fistula , grade 4 bowel obstruction gastrointestinal perforation history intraabdominal abscess 6 month prior day 0 pregnant lactating patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>platinum resistant ovarian cancer</keyword>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>platinum resistant cancer</keyword>
</DOC>